Improving the BBB integrity by reducing MMP-2 serum concentration as the primary outcome of this study and to establish immune homeostasis seem to be an integral component for decreasing both MS-specific symptomology and disease progression. The gene discussed is MMP2; the disease is myeloid sarcoma.